Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California.
IPO Year: 2021
Exchange: NASDAQ
Website: zymergen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2022 | Market Perform | Cowen | |
| 1/12/2022 | $6.50 | Reduce → Hold | HSBC Securities |
| 10/15/2021 | Market Perform | Cowen | |
| 9/27/2021 | $12.00 | Neutral → Underweight | JP Morgan |
| 8/31/2021 | $56.00 → $13.00 | Buy → Neutral | UBS |
| 8/4/2021 | $43.00 → $7.00 | Buy → Underperform | BofA Securities |
| 8/4/2021 | Outperform → Market Perform | Cowen & Co. | |
| 8/4/2021 | $55.00 → $12.00 | Buy → Neutral | Goldman Sachs |
| 8/4/2021 | $8.00 | Hold → Reduce | HSBC |
| 8/4/2021 | $12.00 | Overweight → Neutral | JP Morgan |
SC 13G/A - Zymergen Inc. (0001645842) (Subject)
SC 13G - Zymergen Inc. (0001645842) (Subject)
SC 13G - Zymergen Inc. (0001645842) (Subject)
SC 13G/A - Zymergen Inc. (0001645842) (Subject)
SC 13G - Zymergen Inc. (0001645842) (Subject)
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, and Zymergen (NASDAQ:ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome t
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac
EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficiency, and reliability of operations for its existing platform. Octant has now more than doubled its initial investment through the purchase of an additional six RAC units, vastly increasing the system's throughput, capabilities, and ability to run complex workflows. "We've been extremely pleased with the performance of our current RAC System and are l
EMERYVILLE, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use in high performance 3D printing applications. 3D4Makers will convert the powder to filament, offering its first-ever polyimide filament to customers for use across a wide range of applications including aerospace, automotive, and transportation. Polyimide is a very high-strength polymer that is inherently flame retardant, has excellent insulating properties and excellent thermal stability. Zymergen Z2 polyimide is easy to 3D print and demonstrates low warp while having significant Z streng
EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company"), today announced it has entered into an agreement with Octant for the sale of a modular automation system to scale Octant's next-generation platform to develop breakthrough medicines. Zymergen's complete automation solution includes modular hardware, modern web-based software, custom and turnkey workflows, and active monitoring and support. This technology will be incorporated into Octant's existing platform that uses synthetic biology, high throughput multiplexed assays, synthetic chemistry, and computation to engineer and interrogate drugs, proteins, and signaling pathways. Over the course o
- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS announces effectiveness of registration statement on Form S-4 - - Meeting of DYNS stockholders to approve proposed business combination scheduled for Tuesday, June 7, 2022 at 10:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. ("Senti Bio"), a leading gene circuit company, today announced that it has secured additional funding from Leaps by Bayer, the impact investment arm of Bayer AG, in the form of a
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the first quarter ended March 31, 2022. "Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process," said Zymergen's interim CEO, Jay Flatley. "We now have the infrastructure to support great execution and the delivery of products across our three businesses of Advanced Materials, Drug Discovery and Automation." Preliminary First Quarter 2022 Financial ResultsTotal r
EMERYVILLE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company"), today announced the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference held in Las Vegas, NV. Zymergen's management is scheduled to present on Tuesday, May 10th at 10:55 a.m. Pacific Time / 1:55 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company's website at: https://investors.zymergen.com/. About ZymergenZymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products,
EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world. Investor Contactinvest
EMERYVILLE, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the fourth quarter and full year ended December 31, 2021. "Our strategy is committed to bringing products to market by designing and producing molecules, microbes, and materials for diverse end markets across advanced materials, drug discovery and automation," said Zymergen's interim CEO, Jay Flatley. "We have implemented a rigorous product development process which evaluates programs through stringent phase gates that verify aspects of the market, the product, and the team resources to fully develop that product to laun
Cowen resumed coverage of Zymergen with a rating of Market Perform
HSBC Securities upgraded Zymergen from Reduce to Hold and set a new price target of $6.50
Cowen resumed coverage of Zymergen with a rating of Market Perform
JP Morgan downgraded Zymergen from Neutral to Underweight and set a new price target of $12.00
UBS downgraded Zymergen from Buy to Neutral and set a new price target of $13.00 from $56.00 previously
BofA Securities downgraded Zymergen from Buy to Underperform and set a new price target of $7.00 from $43.00 previously
Cowen & Co. downgraded Zymergen from Outperform to Market Perform
Goldman Sachs downgraded Zymergen from Buy to Neutral and set a new price target of $12.00 from $55.00 previously
HSBC downgraded Zymergen from Hold to Reduce and set a new price target of $8.00
JP Morgan downgraded Zymergen from Overweight to Neutral and set a new price target of $12.00
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the first quarter ended March 31, 2022. "Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process," said Zymergen's interim CEO, Jay Flatley. "We now have the infrastructure to support great execution and the delivery of products across our three businesses of Advanced Materials, Drug Discovery and Automation." Preliminary First Quarter 2022 Financial ResultsTotal r
EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world. Investor Contactinvest
EMERYVILLE, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the fourth quarter and full year ended December 31, 2021. "Our strategy is committed to bringing products to market by designing and producing molecules, microbes, and materials for diverse end markets across advanced materials, drug discovery and automation," said Zymergen's interim CEO, Jay Flatley. "We have implemented a rigorous product development process which evaluates programs through stringent phase gates that verify aspects of the market, the product, and the team resources to fully develop that product to laun
EMERYVILLE, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 22nd, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results, business developments and outlook. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way
EMERYVILLE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company"), a leading biofacturing company, today reported preliminary financial results for the third quarter ended September 30, 2021. Since the previous business update in August, the Company has reviewed potential market opportunities and its related portfolio, using a rigorous evaluation process applied to current and potential market segments. As a result of this review, the Company will focus on a smaller number of programs that it believes capitalize on its capabilities and provide clear commercial opportunities. Accordingly, several programs will be discontinued, including: The electronics fi
EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (NASDAQ:ZY) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd, 2021. The company's management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biofacturing company using biology to reimagine the world. Zymergen partners with nature to design, develop and manufacture bio-based breakthrough products that deliver value to customers in a
Jay Flatley, Chairman of the Board, Appointed Acting CEO; Josh Hoffman to Step Down Conference Call to be Held at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time Today EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company"), today provided a business update regarding its commercial product pipeline and financial forecast. Zymergen recently became aware of issues with its commercial product pipeline that will impact the Company's delivery timeline and revenue projections. Accordingly, the Company no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022. During the quarter, several key target customers encou
15-12G - Zymergen Inc. (0001645842) (Filer)
EFFECT - Zymergen Inc. (0001645842) (Filer)
POS AM - Zymergen Inc. (0001645842) (Filer)
S-8 POS - Zymergen Inc. (0001645842) (Filer)
S-8 POS - Zymergen Inc. (0001645842) (Filer)
8-K - Zymergen Inc. (0001645842) (Filer)
25-NSE - Zymergen Inc. (0001645842) (Subject)
425 - Zymergen Inc. (0001645842) (Subject)
8-K - Zymergen Inc. (0001645842) (Filer)
425 - Zymergen Inc. (0001645842) (Subject)